GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (FRA:1RV) » Definitions » Accumulated other comprehensive income (loss)

Rhythm Pharmaceuticals (FRA:1RV) Accumulated other comprehensive income (loss) : €-0.0 Mil (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Rhythm Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was €-0.0 Mil.

Rhythm Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2024 (€-0.5 Mil) to Dec. 2024 (€-0.0 Mil) but then declined from Dec. 2024 (€-0.0 Mil) to Mar. 2025 (€-0.0 Mil).

Rhythm Pharmaceuticals's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 (€-0.1 Mil) to Dec. 2023 (€0.1 Mil) but then declined from Dec. 2023 (€0.1 Mil) to Dec. 2024 (€-0.0 Mil).

Rhythm Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Rhythm Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 - -0.09 0.12 -0.04

Rhythm Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.57 -0.54 -0.04 -0.05

Rhythm Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Rhythm Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (FRA:1RV) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
SLNO MRUS PCVX SRPT AKRO RNA ACAD CYTK PTCT KRYS VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
RYTM:USA
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Website
https://www.rhythmtx.com
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Rhythm Pharmaceuticals Headlines

No Headlines